Chris Cox joined The Medicines Company (MDCO) in February 2016 as Executive Vice President and Chief Corporate Development Officer. Prior to joining MDCO, Chris spent over 20 years as a corporate attorney, most recently at Cadwalader, Wickersham & Taft LLP, where he was Co-Chair of the Firm’s Corporate Group and a member of its Management Committee. He joined Cadwalader in January 2012. Previously, he was a Partner at Cahill Gordon & Reindel LLP. Chris has extensive experience in a wide array of corporate, financial and business-related matters, including mergers and acquisitions, joint ventures, restructurings, spin-offs and IP licensing and monetization transactions. He has been selected by The American Lawyer as a “Dealmaker of the Year” and was named an M&A Atlas "Top 50 Global M&A Lawyer." He has also been recognized for his work in mergers, acquisitions and buyouts by Chambers and The Legal 500 and has been named a leading lawyer by the Lawdragon 500 Annual Guide. Chris has been a Director of Datawatch Corporation since August 21, 2012. He received a B.S. and J.D. from the University of Missouri, where he was a member of the Missouri Law Review.
Executive Vice President